Andrew P. Coatesworth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrew P. Coatesworth has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
A. Nicolaides
Department of Otolaryngology, Head and Neck Surgery, York Hospital, York, UK
3 shared publications- Paul Nix
Department of Otolaryngology, Hull Royal Infirmary, Hull, UK
3 shared publications
Latest Publications
- 22 March 2007
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 61 (4) , 543-544
How good are your notes? The importance of precision
- 22 March 2007
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 61 (4) , 543-544
How good are your notes? The importance of precision
- 25 November 2005
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 60 (1) , 80-84
Thyroid cancer review 3: management of medullary and undifferentiated thyroid cancer
This is the last of the three review articles dealing with thyroid cancer. Over 90% of thyroid cancer is of the differentiated type associated with a very good 10-year disease-free survival rate. In contrast, the rare forms of thyroid cancer which comprise medullary thyroid cancer arising from parafollicluar C cells, Hurthle cell carcinoma, anaplastic carcinoma, thyroid lymphoma and squamous cell carcinoma are typically associated with a poorer survival rate. Management is based upon small retrospective cohort studies.
- 25 November 2005
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 60 (1) , 80-84
Thyroid cancer review 3: management of medullary and undifferentiated thyroid cancer
This is the last of the three review articles dealing with thyroid cancer. Over 90% of thyroid cancer is of the differentiated type associated with a very good 10-year disease-free survival rate. In contrast, the rare forms of thyroid cancer which comprise medullary thyroid cancer arising from parafollicluar C cells, Hurthle cell carcinoma, anaplastic carcinoma, thyroid lymphoma and squamous cell carcinoma are typically associated with a poorer survival rate. Management is based upon small retrospective cohort studies.
- 18 November 2005
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 59 (12) , 1459-1463
Thyroid cancer review 2: management of differentiated thyroid cancers
This is the second review article on thyroid cancer dealing with the common differentiated types that comprise 90% of thyroid cancers. Despite clinical management guidelines offered by a number of organisations including the British Association of Otolaryngologists and Head and Neck Surgeon, The British Thyroid Association, The American Association Of Endocrinologists, The American Thyroid Association and the National Cancer Centre Network, debate regarding the management of differentiated thyroid cancer continues. This is because of the absence of good quality research evidence as a consequence of the natural history of this disease.
- 18 November 2005
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 59 (12) , 1459-1463
Thyroid cancer review 2: management of differentiated thyroid cancers
This is the second review article on thyroid cancer dealing with the common differentiated types that comprise 90% of thyroid cancers. Despite clinical management guidelines offered by a number of organisations including the British Association of Otolaryngologists and Head and Neck Surgeon, The British Thyroid Association, The American Association Of Endocrinologists, The American Thyroid Association and the National Cancer Centre Network, debate regarding the management of differentiated thyroid cancer continues. This is because of the absence of good quality research evidence as a consequence of the natural history of this disease.
- 18 October 2005
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 59 (11) , 1340-1344
Thyroid cancer review 1: presentation and investigation of thyroid cancer
Thyroid cancer is uncommon with an estimated lifetime risk of 0.8% for women and 0.3% for men. The incidence appears to be increasing by 4% per year and is currently the eighth commonest cancer in women. Managing thyroid cancer is challenging, as no prospective randomised trials exist. Most of the information is derived from large patient cohorts in which therapy has not been randomly assigned. This is the first of the three review papers we have written on the management of thyroid cancer.
- 18 October 2005
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 59 (11) , 1340-1344
Thyroid cancer review 1: presentation and investigation of thyroid cancer
Thyroid cancer is uncommon with an estimated lifetime risk of 0.8% for women and 0.3% for men. The incidence appears to be increasing by 4% per year and is currently the eighth commonest cancer in women. Managing thyroid cancer is challenging, as no prospective randomised trials exist. Most of the information is derived from large patient cohorts in which therapy has not been randomly assigned. This is the first of the three review papers we have written on the management of thyroid cancer.